Trafalgar International (GCAN) Net Income towards Common Stockholders (2017 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Net Income towards Common Stockholders of -$33376.0 for Q1 2026, up 67.76% year-over-year from -$19895.6 in Q1 2025, and down 109.88% quarter-over-quarter from $337757.0 in Q4 2025.
Trafalgar International (GCAN) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$33376.0 for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 67.76% year-over-year to -$33376.0; the TTM figure through Mar 2026 stood at -$122571.0 (up 48.49% YoY), while the FY2025 annual figure was -$331612.0, down 85.22% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$33376.0, down from $337757.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $337757.0 in Q4 2025, with the low at -$390853.0 in Q2 2025.
- The 5-year median for Net Income towards Common Stockholders is -$46165.0 (2024), against an average of -$56105.5.
- Peak annual rise in Net Income towards Common Stockholders reached 879.18% in 2025, while the deepest fall reached 770.17% in 2025.
- Greater Cannabis Company's Net Income towards Common Stockholders stood at -$47401.0 in 2022, then rose by 1.14% to -$46861.0 in 2023, then increased by 7.5% to -$43348.0 in 2024, then surged by 879.18% to $337757.0 in 2025, then plunged by 109.88% to -$33376.0 in 2026.
- Business Quant data shows GCAN's Net Income towards Common Stockholders at -$33376.0 in Q1 2026, $337757.0 in Q4 2025, and -$36099.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | -33,376.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | 337,757.00 |
| Sep 30, 2025 | -36,099.00 |
| Jun 30, 2025 | -390,853.00 |
| Mar 31, 2025 | -103,511.00 |
| Dec 31, 2024 | -43,348.00 |
| Sep 30, 2024 | -46,165.00 |
| Jun 30, 2024 | -44,917.00 |
| Mar 31, 2024 | -44,611.00 |
| Dec 31, 2023 | -46,861.00 |
| Sep 30, 2023 | -53,430.00 |
| Jun 30, 2023 | -45,043.00 |
| Mar 31, 2023 | -43,068.00 |
| Dec 31, 2022 | -47,401.00 |
| Sep 30, 2022 | -102,776.00 |
| Jun 30, 2022 | -62,405.00 |
| Mar 31, 2022 | -147,686.00 |
| Dec 31, 2021 | -196,331.00 |
| Sep 30, 2021 | -252,278.00 |
| Jun 30, 2021 | -38,964.00 |